SALT LAKE CITY, Oct. 6, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held November 7-11, 2010 in Atlanta, Georgia.
Data will be presented on MPI-0485520, a potent and selective oral anti-interferon (OAI) in preclinical development. MPI-0485520 targets I kappa B kinase epsilon (IKK epsilon) and TANK-binding kinase 1 (TBK1), which are required for the initiation of certain inflammatory immune responses involving type-I interferons (IFN alpha/beta).
|Title:||Inhibition of Cytosolic Nucleic Acid Receptor|
|Pathways Using the Small Molecule IKK|
|epsilon/TBK1 Kinase Inhibitor MPI-0485520|
|Date & Time:||Monday, November 08, 2010; 9 AM - 6 PM|
Preclinical studies of MPI-0485520 have demonstrated potent and selective suppression of IFN alpha/beta and other pro-inflammatory cytokines involved in autoimmune disorders such as systemic lupus erythematosus. The compound also exhibits high oral bioavailability and a favorable ADME/PK profile. Additionally, recent publications have identified IKK epsilon as a promising and novel therapeutic target for the treatment of rheumatoid arthritis.About Myrexis, Inc. Myrexis, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer. The Company has leveraged a unique understanding of the genetic causes of human disease to generate a strong pipeline of clinical and preclinical product candidates. These include compounds with distinct mechanisms of action and novel chemical structures that have first-in-class and/or best-in-class therapeutic potential. Myrexis is led by an experienced management team with expertise in human genetics, protein-protein interaction technology, chemical proteomic drug discovery and clinical and commercial development.